摘要
目的:探讨同期NP方案化疗与后程加速调强适形放射治疗Ⅲ期非小细胞肺癌的耐受性及疗效.方法:收治的56位患者,其中鳞癌32例,腺癌19例,大细胞未分化癌3例,腺鳞癌2例,KPS均70以上;按1997 UICC肺癌临床分期,Ⅲa期24例,Ⅲb期32例.化疗长春瑞滨(NVB)于第1、8天20 mg/m2,顺铂(DDP)于第1～5天20 mg/日静滴,28天一周期,共化疗4～6个周期.放疗先采取常规前后野对穿照射,4周剂量40Gy/20～21次以后改为调强适形放射治疗,包括原发病灶及转移淋巴结,剂量2.5～3.0Gy/次,5次/周,2～2.5周共2 5～30Gy/10～12次,总剂量为65～70Gy.结果:全组中位生存时间为18.9个月,1、2年生存率分别为76.8%、48.2%.急性毒副作用白细胞与血小板降低发生率为92.9%、80.4%,放射性食管炎发生率21.4%,放射性肺炎总发生率26.8%.结论:同期NP方案化疗与后程加速调强适形放射治疗Ⅲ期非小细胞肺癌,患者耐受性良好,疗效较满意.
Purpose:To evaluate the effect and tolerance of late course accelerated intensity modulated radiotherapy(IMRT) combined with NP concurrent chemotherapy for stage Ⅲ non-small cell lung cancer. Methods:From January 2000 to March 2002, 56 patients with 32 sq uamous carcinoma,19 adenocarcinoma, 3 undeferented carcinoma and 2 squamous-ade nocarcinoma were treated.The radiotherapy was first conventional fraction to a d ose of 40Gy/20～21 times,then the late course treatment was given by IMRT at 2. 5～3.0GY/10～12 times, the total dose was 65～70 Gy. The protocal of chemotherap y was NVB 20mg/m 2 d1、8, DDP 20mg per day d1-5). Results:The median suvival time was 18.9 months, the 1,2 year s uvival rate were 76.8%、48.2%. The main side effects were leucopenia(92.9%) and platelate depression(80.4%). The acute radiation reactions were esophagitis and pneumonitis,21.4% and 26.8%. Conclusions:Intensity modulated radiotherapy combined with NP c oncurrent chemotherapy for stage Ⅲ NSCLC is well tolerated,and is able to imp rove overall response and the survival time.
出处
《中国癌症杂志》
CAS
CSCD
2005年第1期46-48,51,共4页
China Oncology
关键词
非小细胞肺癌
放射治疗
化学治疗
长春瑞滨
顺铂
non-small cell lung cancer
radiotherapy
che motherapy
vinrelbine
cisplatin
